MiMedx Group, Inc.

MiMedx Group, Inc. Earnings Recaps

MDXG Health Care 1 recap
Next earnings: November 4, 2026 (estimated) · full calendar
Q2 2026 Jul 31, 2026

Shares declined 2.1% following Q2 results and acquisition news as investors likely digested ongoing challenges in wound care despite surgical growth and the transformational Sanara MedTech deal.

Key takeaways
  • Surgical revenue grew 15% year-over-year, continuing momentum from prior quarters.
  • Overall company revenue rose 9% sequentially from Q1 to Q2.
  • Wound care remains under pressure due to Medicare reimbursement changes causing market disruption.
  • The Sanara MedTech acquisition (~$35/share) will shift MiMedx's revenue mix to 75% surgical and 25% wound post-close.
  • Expected 2027 combined company revenue above $400 million with double-digit growth and adjusted EBITDA margin exceeding 20%, driven by $20 million in cost synergies.
Full recap

Go deeper on MDXG and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.